DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02686177

ANGIOSAFE 1

CompletedPhase 4

Effect of GLP-1 on Angiogenesis

Effect of GLP-1 on Angiogenesis, Angiosafe Type 2 Diabetes Study 1

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

50

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥25•HbA1c ≥6.5%

Primary endpoint

•ANGPTL4 concentration

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02686177
Org study IDP140710
Secondary ID2015-002930-35IDRCB

Timeline

Milestones

Study first posted2016-02-19estimated
Study start2016-05-18actual
Primary completion2017-08-08actual
Study completion2021-05-28actual
Last update posted2021-06-15actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetic patients (ADA criteria)
•Age > 18 years
•Obesity (BMI >= 25 kg/m2)
•HbA1c > 6.5 %
•Treatment with Metformin and/or secretagogues
•Effective contraception (women)

Exclusion criteria

•Treatment with Exenatide, Liraglutide or other incretinergic regimen (<1 month before recruitment)
•Type 1 diabetes
•acute disease or infection
•chronic renal failure (MDRD eGFR≤50 mL/min)
•recent cardiovascular event or surgery (<3 months)
•pancreatitis history
•anti-VEGF treatment
•untreated cancer
•immunological disorders
•pregnancy and lactation
•Vulnerable people : deprivation of Liberty safeguards
•hypersensitivity to the active substance or to any of the excipients of the investigational drug
•diabetic ketoacidosis
•heart failure stage 3 or 4 (NYHA III-IV)
•Hepatic insufficiency
•inflammatory bowel disease and gastroparesis
•No affiliation to the social security

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
3
Other (unclassified)
2

Cardiometabolic biomarkers

3 endpoints
Secondary/protocol endpoint

Difference of ANGPT2 concentration at 4 weeks of treatment from baseline in Liraglutide and control group

Time frame:4 weeks

change from baseline, improvement

Secondary/protocol endpoint

Difference of endothelial circulating progenitor cells (CD34+KDR+) concentration at 4 weeks of treatment from baseline in Liraglutide and control group

Time frame:4 weeks

change from baseline, improvement

Secondary/protocol endpoint

Difference of Circulating soluble adhesion molecules as endothelial activation markers: ICAM-1 and VCAM-1 concentration at 4 weeks of treatment from baseline (Liraglutide versus control group)

Time frame:4 weeks

change from baseline, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group

Time frame:At 1 month

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Difference of AngiomiR-126 expression at 4 weeks of treatment from baseline in Liraglutide and control group

Time frame:4 weeks

change from baseline, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.